Balyasny Asset Management
IKT icon

Balyasny Asset Management’s Inhibikase Therapeutics IKT Stock Holding History

Balyasny Asset Management’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$29.7K Buy
+17,674
New +$31.4K ﹤0.01% 2789
2025
Q2 		– Sell
-81,161
Closed -$178K – 3067
2025
Q1 		$178K Buy
+81,161
New +$204K ﹤0.01% 2610

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Balyasny Asset Management's IKT Position: Q1 2026 in Review

Balyasny Asset Management opened a new position in Inhibikase Therapeutics (IKT) in Q1 2026: 17,674 shares worth $29.7K. The stake represents ﹤0.01% of the portfolio and ranks #2789 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in IKT as recently as Q1 2025.

Balyasny Asset Management first reported a position in IKT in Q1 2025 and has held it in 2 quarters since. The position peaked at $178K in Q1 2025. 104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • Balyasny Asset Management held 17,674 shares of Inhibikase Therapeutics worth $29.7K as of Q1 2026.
  • Inhibikase Therapeutics was a new Balyasny Asset Management position in Q1 2026.
  • Inhibikase Therapeutics made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #2789 holding.
  • Balyasny Asset Management first reported a position in Inhibikase Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • Balyasny Asset Management's Inhibikase Therapeutics position peaked at $178K in Q1 2025.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.